To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Marinol, a registered trademark of Unimed Pharmaceuticals, Inc. is the commercial name for a product containing dronabinol, which is the INN of Δ9-tetrahydrocannabinol (THC). THC is a naturally occurring component in cannabis. Despite the apparent similarities between dronabinol and THC, it is worth noting that dronabinol is synthesized THC, meaning that the drug dronabinol does not house all the chemical constituents present in THC.
Marinol is an FDA-approved cannabinoid and is prescribed as an appetite stimulant, primarily for AIDS, chemotherapy and gastric bypass patients. Marinol was also FDA approved as an anti-nauseant, in order to better address the nauseau experienced after chemotherapy treatments. Compare Sativex, a mouth spray for neuropathic pain of multiple sclerosis sufferers approved for use in Canada and in the US as of 2006. While Marinol can serve as an anti-emetic and appetite booster, its immunomodulative effect should be taken into account in the treatment of any compromised immune condition.
Comparisons to medicinal cannabis
Marinol is known to produce side-effects similar to cannabis intoxication. Some have posited that Marinol lacks beneficial properties of cannabis, which contains more than 60 cannabinoids, including cannabidiol (CBD), thought to be the major anti-convulsant that helps multiple sclerosis patients, and cannabichromene (CBC), an anti-inflammatory which may contribute to the pain-killing effect of cannabis. Others have countered that the effects of all of cannabis's cannabinoids have not been completely studied and are not fully understood to be beneficial.
It takes over one hour for Marinol to reach full systemic effect, compared to minutes for smoked or vaporized cannabis. Some patients accustomed to inhaling just enough cannabis smoke to manage symptoms have complained of too-intense intoxication via Marinol's predetermined dosages. This powerful psychoactive effect, however, has led to recreational use of Marinol. Many have said that Marinol produces a more acute psychedelic effect than cannabis and it has been speculated that this disparity can be explained by the moderating effect of the many non-THC cannibinoids present in cannabis. Mark Kleiman, director of the Drug Policy Analysis Program at UCLA's School of Public Affairs had this to say about Marinol-- "It wasn't any fun and made the user feel bad," Kleiman says, "so it could be approved without any fear that it would penetrate the recreational market, and then used as a club with which to beat back the advocates of whole cannabis as a medicine." United States federal law currently registers Dronabinol as a Schedule III controlled substance, but all other Cannabis remains Schedule I, except Nabilone. Some taking Marinol to manage nausea have stated that often the Marinol capsule is expelled before it can take effect.
Since at least 1986, the trend has been for THC in general, and especially the Marinol preparation, to be downgraded to less and less stringently-controlled schedules of controlled substances, in the U.S. and internationally.
On July 13, 1986, the Drug Enforcement Administration (DEA) issued a Final Rule and Statement of Policy authorizing the "Rescheduling of Synthetic Dronabinol in Sesame Oil and Encapsulated in Soft Gelatin Capsules From Schedule I to Schedule II"(DEA 51 FR 17476-78). This permitted medical use of Marinol, albeit with the severe restrictions associated with Schedule II status. For instance, refills of Marinol prescriptions were not permitted. At its 1045th meeting, on April 29, 1991, the Commission on Narcotic Drugs, in accordance with article 2, paragraphs 5 and 6, of the Convention on Psychotropic Substances, decided that Δ9-tetrahydrocannabinol (also referred to as Δ9-THC) and its stereochemical variants should be transferred from Schedule I to Schedule II of that Convention. This released Marinol from the restrictions imposed by Article 7 of the Convention.
An abstract published in the April-June 1998 issue of the Journal of Psychoactive Drugs found that "Healthcare professionals have detected no indication of scrip-chasing or doctor-shopping among the patients for whom they have prescribed dronabinol". The authors suggested that Marinol had a low potential for abuse.
In 1999, Marinol was rescheduled from Schedule II to III of the Controlled Substances Act, reflecting a finding that THC had a potential for abuse less than that of cocaine, and heroin. This rescheduling comprised part of the argument for a 2002 petition for cannabis rescheduling in the United States, in which petitioner Jon Gettman noted, "Cannabis is a natural source of dronabinol (THC), the ingredient of Marinol™, a Schedule III drug. There are no grounds to schedule cannabis in a more restrictive schedule than Marinol™".
At its 33rd meeting, the World Health Organization Expert Committee on Drug Dependence recommended transferring tetrahydrocannabinol to Schedule IV of the Convention, citing its medical uses and low abuse potential. This would put THC in the Convention's least stringently-controlled Schedule.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dronabinol". A list of authors is available in Wikipedia.|